Cannara Historical Cash Flow

LOVE Stock  CAD 0.70  0.02  2.78%   
Analysis of Cannara Biotech cash flow over time is an excellent tool to project Cannara Biotech future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Dividends Paid of 0.0 or Capital Expenditures of 15.4 M as it is a great indicator of Cannara Biotech ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Cannara Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cannara Biotech is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

About Cannara Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Cannara balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Cannara's non-liquid assets can be easily converted into cash.

Cannara Biotech Cash Flow Chart

At this time, Cannara Biotech's Net Borrowings is fairly stable compared to the past year. Depreciation is likely to climb to about 6 M in 2024, whereas Investments are likely to drop (11.4 M) in 2024.

Change To Inventory

The increase or decrease in the amount of inventory a company has over a certain period.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Total Cashflows From Investing Activities

The net amount of cash used in or generated from a company's investment activities, such as purchasing or selling assets, during a reporting period.
Most accounts from Cannara Biotech's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Cannara Biotech current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
At this time, Cannara Biotech's Net Borrowings is fairly stable compared to the past year. Depreciation is likely to climb to about 6 M in 2024, whereas Investments are likely to drop (11.4 M) in 2024.
 2021 2023 2024 (projected)
Stock Based Compensation349.5K1.6M865.0K
Change To Liabilities2.4M2.8M2.0M

Cannara Biotech cash flow statement Correlations

-0.270.78-0.3-0.420.94-0.960.810.80.73-0.810.74-0.80.660.75-0.530.67
-0.27-0.220.390.84-0.080.26-0.38-0.60.150.49-0.530.25-0.41-0.3-0.110.18
0.78-0.220.25-0.20.63-0.860.460.860.34-0.890.33-0.370.590.37-0.090.76
-0.30.390.250.71-0.30.23-0.710.0-0.340.06-0.810.75-0.46-0.730.670.19
-0.420.84-0.20.71-0.190.45-0.72-0.50.030.42-0.750.65-0.64-0.580.30.2
0.94-0.080.63-0.3-0.19-0.840.680.630.91-0.680.69-0.720.490.72-0.560.73
-0.960.26-0.860.230.45-0.84-0.79-0.81-0.580.82-0.670.78-0.72-0.690.46-0.68
0.81-0.380.46-0.71-0.720.68-0.790.520.55-0.620.93-0.970.870.94-0.780.35
0.8-0.60.860.0-0.50.63-0.810.520.3-0.870.5-0.430.530.4-0.050.48
0.730.150.34-0.340.030.91-0.580.550.3-0.460.61-0.610.360.7-0.650.7
-0.810.49-0.890.060.42-0.680.82-0.62-0.87-0.46-0.620.48-0.77-0.620.24-0.73
0.74-0.530.33-0.81-0.750.69-0.670.930.50.61-0.62-0.890.80.96-0.720.31
-0.80.25-0.370.750.65-0.720.78-0.97-0.43-0.610.48-0.89-0.73-0.90.8-0.31
0.66-0.410.59-0.46-0.640.49-0.720.870.530.36-0.770.8-0.730.85-0.620.47
0.75-0.30.37-0.73-0.580.72-0.690.940.40.7-0.620.96-0.90.85-0.840.45
-0.53-0.11-0.090.670.3-0.560.46-0.78-0.05-0.650.24-0.720.8-0.62-0.84-0.27
0.670.180.760.190.20.73-0.680.350.480.7-0.730.31-0.310.470.45-0.27
Click cells to compare fundamentals

Cannara Biotech Account Relationship Matchups

Cannara Biotech cash flow statement Accounts

201920202021202220232024 (projected)
Change To Inventory(2.5M)(3.4M)(8.2M)(8.3M)(7.5M)(7.1M)
Investments(8.6M)(30.8M)(15.3M)(9.5M)(10.9M)(11.4M)
Change In Cash(18.7M)388.1K4.0M(7.8M)(7.0M)(6.6M)
Net Borrowings(235.5K)(562.7K)10.1M27.6M31.7M33.3M
Free Cash Flow(18.1M)(33.2M)(21.5M)(4.4M)(5.1M)(5.4M)
Change In Working Capital(289.6K)(3.8M)(11.5M)(6.1M)(5.5M)(5.8M)
Begin Period Cash Flow26.5M7.8M8.2M12.1M13.9M12.4M
Total Cashflows From Investing Activities(21.6M)(8.6M)(30.8M)(15.3M)(17.6M)(18.5M)
Other Cashflows From Financing Activities3.3M(1.1M)(1.5M)(2.2M)(1.9M)(1.9M)
Depreciation2.4M2.9M3.9M4.9M5.7M6.0M
Other Non Cash Items1.1M(169.2K)(659.0K)(2.2M)(2.0M)(1.9M)
Capital Expenditures9.2M30.6M15.1M9.9M8.9M15.4M
Total Cash From Operating Activities(9.3M)(2.1M)(6.1M)5.4M6.3M6.6M
Change To Account Receivables28.7K(2.8M)(5.7M)(2.0M)(1.8M)(1.9M)
Change To Operating Activities(658.5K)253.0K(274.1K)23.5K27.0K28.3K
Net Income(12.5M)(1.5M)2.3M6.9M8.0M8.4M
Total Cash From Financing Activities(914.8K)33.3M25.5M(3.7M)(3.3M)(3.2M)
End Period Cash Flow7.8M8.2M12.1M4.3M3.8M3.7M
Change To Netincome4.1M1.7M189.3K(937.6K)(843.9K)(801.7K)
Change To Liabilities938.2K1.1M2.6M2.4M2.8M2.0M
Stock Based Compensation782.1K331.6K349.5K1.8M1.6M865.0K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cannara Stock Analysis

When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.